Reconstitution of lymphocyte subsets after peripheral blood stem cell transplantation: two-color flow cytometric analysis

Bone Marrow Transplant. 1994 Apr;13(4):377-81.

Abstract

The reconstitution of lymphocyte subsets after high-dose chemotherapy followed by peripheral blood stem cell transplantation (PBSCT) was studied using two-color flow cytometry in 14 patients with acute leukemia (four AML and two ALL) and malignant lymphoma (six NHL and two HD). The CD3+HLA-DR+ lymphocytes (activated T cells) and CD8+ lymphocytes increased markedly by 4 weeks after PBSCT. Most of the increased CD8+ lymphocytes were CD11b-, S6F1+ cells and CD8+CD11b+ cells remained low throughout the follow-up period. The CD4+ lymphocytes remained below the normal range up to 34 weeks after PBSCT. The ratio of CD4+ to CD8+ lymphocytes (CD4/CD8 ratio) transiently increased and then decreased below 1.0 at 2 weeks after PBSCT. The CD19+ lymphocytes and the CD3-CD16+CD56+ lymphocytes returned to normal levels in the early period. The CD4+CD45RA+ lymphocytes (suppressor-inducer) decreased to below the normal range, while the CD4+CD45RO+ lymphocytes (helper-inducer) increased more rapidly than the CD4+CD45RA+ lymphocytes. This study shows that an immunosuppressed state exists after PBSCT as is seen after bone marrow transplantation (BMT) and that B cell reconstitution is more rapid in PBSCT than in BMT.

MeSH terms

  • Acute Disease
  • Adolescent
  • Adult
  • Blood Component Transfusion*
  • Busulfan / adverse effects
  • Busulfan / therapeutic use
  • Combined Modality Therapy
  • Etoposide / adverse effects
  • Etoposide / therapeutic use
  • Female
  • Flow Cytometry / methods*
  • Graft Survival
  • Graft vs Host Disease / prevention & control
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Immunophenotyping / methods*
  • Leukemia, Myeloid / blood*
  • Leukemia, Myeloid / drug therapy
  • Leukemia, Myeloid / therapy
  • Leukocyte Count
  • Leukopenia / chemically induced
  • Lymphocyte Subsets*
  • Lymphoma / blood*
  • Lymphoma / drug therapy
  • Lymphoma / therapy
  • Male
  • Middle Aged
  • Nitrosourea Compounds / adverse effects
  • Nitrosourea Compounds / therapeutic use
  • Platelet Count
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

Substances

  • Nitrosourea Compounds
  • Etoposide
  • Busulfan
  • ranimustine